“Transforming a human first, data-driven microbiome discovery platform to drug development for multiple diseases”
G-NiiB GenieBiome leverages one of the first and largest Asian human microbial data-driven approach to therapeutics development. Our expanding disease-specific microbial datasets compared with a comprehensive control microbial dataset provide a rich source for novel therapeutic candidates. We have the ability to develop novel consortia with beneficial functional and metabolic profiles, to target multiple human diseases.
Turning microbes into novel therapeutics
were derived utilizing large metagenomic microbial datasets and machine-learning approaches to deliver missing microbes and their biologically important functions to restore “dysbiosis” in conditions associated with it.
uses our proprietary approach to isolate human-derived novel health-relevant bacteria candidates and metabolites for pre-clinical experiments with rapid development into effective biotherapeutics for the prevention and treatment of human diseases.
